Imagine if we could tell patients if they are cancer-free, how advanced it is, or which drugs work best for their treatment, all by analyzing a blood or urine sample. Our technology does precisely that. It functionally identifies unique molecules in tiny bubble-like containers called extracellular vesicles that come from diseased cells. These molecules act like gates on cell surfaces, controlling what goes in and out of cells. Since these gates are essential for cell survival and easy to access on the cell surface, they have been the key drug targets for various diseases. They are also carried on the extracellular vesicles. Our technology allows us to observe the diseased cells’ gates in action in their extracellular vesicles and test how drugs affect their function. It informs us about the ID of drug targets present in the diseased cell, the status of the cell, and the best drug candidates for the treatment.
The technology can also serve patients with neurodegenerative and immune-mediated inflammatory diseases. It does not require solid biopsy or imaging. It opens new opportunities for pharmaceutical companies by confirming whether any existing drugs work for the targets, offering a fast track to repurpose current medicines, providing new validation pathways for prioritizing drug candidates, and reducing drug development time and investment. The biotech booster program will provide funding and guidance to choose the best niche for our technology and showcase its potential.
